Zoetis Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kristin C. Peck
- Full Time Employees
- 14,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10 Sylvan Way Parsippany NJ United States of America 07054
- IPO Date
- Feb 1, 2013
- CIK
- 0001555280
- Website
- zoetis.com
- Similar Companies
- Business
- Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.
Company News
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
Blackhill Capital Inc. Cuts Stock Position in Zoetis Inc. $ZTS
3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Zoetis Q2 Earnings Call Highlights
Zoetis (NYSE:ZTS) Hits New 1-Year Low on Analyst Downgrade
Zoetis Q2 Earnings Call Highlights
ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds
Zoetis Inc. (ZTS) Q2 2026 Earnings Call Transcript
Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
Here's What Key Metrics Tell Us About Zoetis (ZTS) Q2 Earnings
Zoetis (ZTS) Surpasses Q2 Earnings Estimates
Zoetis cuts annual forecasts as pet healthcare demand slows
Zoetis Announces Second Quarter 2026 Results